Evaluation of Ovarian Cysts in Breast Cancer Cases on Tamoxifen

被引:0
作者
Mofrad, Malihe Hasanzadeh [1 ,2 ]
Shandiz, Fatemeh Homaei [3 ]
Roodsare, Fatemeh Vahid [1 ,2 ]
Moghiman, Toktam [1 ,2 ]
机构
[1] Mashhad Univ Med Sci, Gynecol Hlth Res Ctr, Mashhad, Iran
[2] Mashhad Univ Med Sci, Canc Res Ctr, Mashhad, Iran
[3] Mashhad Univ Med Sci, Dept Radiat Oncol, Ghaem Hosp, Mashhad, Iran
关键词
Ovarian cyst; tamoxifen; breast cancer; ovarian cancer; ENDOMETRIOID ADENOCARCINOMA; RECEIVING TAMOXIFEN; PREMENOPAUSAL WOMEN; TREATED WOMEN; THERAPY; WOMAN; CARCINOMA;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The anti-estrogen drug, tamoxifen, is one of the most important medications used in the treatment of both advanced and localized breast cancer. However, such tamoxifen use may have some risks related to the endometrium and ovaries. We followed a group of women with breast cancer on tamoxifen for the development of ovarian cysts. Methods: Based on a cross sectional study, 35 pre and post menopausal patients with breast cancer on tamoxifen were followed by pelvic exam and vaginal ultrasonography for 3 cycles of 3 month intervals; occurrence and outcome of ovarian cysts were evaluated. Results: Of the 35 tmoxifen-treated patients enrolled in this study, 21 were postmenopausal and 14 were premenopausal. Their average age was 48.1 +/- 8.7 (range: 29-65 yrs) years. The mean duration of tamoxifen therapy was 30.5 +/- 14 months (range: 12-60 months). Ovarian cysts were diagnosed in 12 (34.3%) patients, with surgery required in 6; pathological examination revealed malignancy in two cases. Conclusion: Development of ovarian cysts is a rather frequent event in women with breast cancer on tamoxifen. The majority of cysts are simple, which may resolve spontaneously or with discontinuation of tamoxifen, but malignancy needs to be ruled out.
引用
收藏
页码:161 / 164
页数:4
相关论文
共 25 条
  • [1] Anteby E., 1993, Harefuah, V125, P267
  • [2] GYNECOLOGIC EFFECTS OF TAMOXIFEN AND THE ASSOCIATION WITH ENDOMETRIAL CARCINOMA
    ASSIKIS, VJ
    JORDAN, VC
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 1995, 49 (03) : 241 - 257
  • [3] BARBIERI RL, 1993, FERTIL STERIL, V59, P459
  • [4] Clarke M, 1998, LANCET, V351, P1451
  • [5] TAMOXIFEN TREATMENT IN PREMENOPAUSAL BREAST-CANCER PATIENTS MAY BE ASSOCIATED WITH OVARIAN OVERSTIMULATION, CYSTIC FORMATIONS AND FIBROID OVERGROWTH
    COHEN, I
    ROSEN, DJD
    ALTARAS, M
    BEYTH, Y
    SHAPIRA, J
    YIGAEL, D
    [J]. BRITISH JOURNAL OF CANCER, 1994, 69 (03) : 620 - 621
  • [6] Simple ovarian cysts in postmenopausal patients with breast carcinoma treated with tamoxifen: Long-term follow-up
    Cohen, I
    Potlog-Nahari, C
    Shapira, J
    Yigael, D
    Tepper, R
    [J]. RADIOLOGY, 2003, 227 (03) : 844 - 848
  • [7] COHEN I, 1998, EJC SUPPL, V34, P22
  • [8] RAPID GROWTH OF LEIOMYOMA IN PATIENT RECEIVING TAMOXIFEN
    DILTS, PV
    HOPKINS, MP
    CHANG, AE
    CODY, RL
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1992, 166 (01) : 167 - 168
  • [9] Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors
    Fisher, B
    Dignam, J
    Bryant, J
    DeCillis, A
    Wickerham, DL
    Wolmark, N
    Costantino, J
    Redmond, C
    Fisher, ER
    Bowman, DM
    Deschenes, L
    Dimitrov, NV
    Margolese, RG
    Robidoux, A
    Shibata, H
    Terz, J
    Paterson, AHG
    Feldman, MI
    Farrar, W
    Evans, J
    Lickley, HL
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (21): : 1529 - 1542
  • [10] Gherman Robert B., 1994, Obstetrics and Gynecology, V84, P717